How do HIV elite controllers do what they do?

Clinical Infectious Diseases

Volumn 51, Issue 2, 2010, Pages 239-241

  Saag, Michael ^a   Deeks, Steven G ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA;

ADAPTIVE IMMUNITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DOWN REGULATION; EX VIVO STUDY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOID TISSUE; NOTE; PATHOGENESIS; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; TARGET CELL; VIREMIA; VIRUS REPLICATION; VIRUS TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGY; PATHOGENICITY; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS;

EID: 77954747572     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653678     Document Type: Note

References (21)

1. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332:209-216.
2. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23:1163-1169.
3. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009; 200:1714-1723.
4. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416.
5. Julg B, Pereyra F, Buzón MJ, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4+ T cells in HIVelite controllers. Clin Infect Dis 2010; 51(2):233-238 (in this issue).
6. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789.
7. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-1021.
8. Ferre AL, Hunt PW, Critchfield JW, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009; 113:3978-3989.
9. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007; 104:6776-6781.
10. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
11. Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 1999; 189:1545-1554.
12. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-133.
13. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replicationcompetent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81:2508-2518.
14. Miura T, Brockman MA, Brumme ZL, et al. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gagprotease from elite controllers of human immunodeficiency virus type 1. J Virol 2009; 83: 140-149.
15. Learmont JC, Geczy AF, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report from the Sydney Blood Bank Cohort. N Engl J Med 1999; 340:1715-1722.
16. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32ra36.
17. Fauci AS, Folkers GK. Investing to meet the scientific challenges of HIV/AIDS. Health Aff (Millwood) 2009; 28:1629-1641.
18. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
19. Andrade A, Bailey JR, Xu J, et al. CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-.B.*5801-positive patient with an undetectable viral load. Clin Infect Dis 2008; 46:e78-82.
20. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-1067.
21. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.